Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Transplant. Mar 18, 2024; 14(1): 87752
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.87752
Table 6 Analysis of outcome in pediatric and adult liver transplantation
Variable
Survived, n = 141 (84.4)
Died, n = 26 (15.6)
P value
Sex 0.130a
Male85 (60.3)11 (42.3)
Female56 (39.7)15 (57.7)
Nationality 0.471a
Bahraini127 (90.1)25 (96.2)
Non-Bahraini14 (9.9)1 (3.8)
Area of residency0.118b
Northern63 (44.7)10 (38.5)
Capital29 (20.6)6 (23.1)
Southern25 (17.7)9 (34.6)
Muharraq24 (17.0)1 (3.8)
Age at liver transplant (yr)48.8 (13.2-58.0)57.5 (47.9-65.2)0.019c
Age group 0.346a
Pediatric42 (29.8)5 (19.2)
Adult 99 (70.2)21 (80.8)
Weight at transplant (kg), (n = 83)52.0 (20.0-70.0)8.0 (5.0-46.0)0.144c
Height at transplant (cm), (n = 76)163.0 (149.0-169.0)138.0 (74.0-149.0)0.101c
Presence of associated diseases139 (98.6)23 (88.5)0.255a
Yes109 (78.4)21 (91.3)
No30 (21.6)2 (8.7)
Type of graft (n = 150)137 (97.2)13 (50.0)0.364a
Living122 (89.1)13 (100)
Cadaveric15 (10.9)0 (0.0)
Donor-recipient relationship (n = 150)137 (97.2)13 (50.0)0.704a
Related donors113 (82.5)10 (76.9)
Unrelated donors24 (17.5)3 (23.1)
Indications of liver transplantation
Hepatitis C virus37 (26.2)5 (19.2)0.623a
Primary sclerosing cholangitis18 (12.8)2 (7.7)0.743a
Nonalcoholic steatohepatitis15 (10.6)4 (15.4)0.503a
Hepatic cellular carcinoma14 (9.9)6 (23.1)0.092a
Biliary atresia13 (9.2)3 (11.5)0.718a
Hepatitis B virus13 (9.2)2 (7.7)1.000a
Autoimmune hepatitis11 (7.8)1 (3.8)0.694a
Metabolic diseases7 (5.0)0 (0.0)0.597a
Intra- or post-LT complications (n = 150)138 (97.9)11 (42.3)0.537a
Yes85 (61.6)8 (72.7)
No53 (38.4)3 (27.7)
Post-LT N-acetylcysteine use50/66 (75.8)46/52 (88.5)0.098
Liver transplant countries0.582b
Middle East 86 (61.0)19 (73.1)
Asia & Pacific 51 (36.2)8 (30.7)
Europe4 (2.8)0 (0.0)
North America 3 (2.1)0 (0.0)
Follow-up duration (yr)7.5 (3.9-10.6)1.5 (0.3-3.2)< 0.001c